Probity Advisors’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.6M Sell
8,297
-650
-7% -$70K 0.23% 76
2026
Q2
$627K Sell
8,947
-197
-2% -$10.2K 0.09% 141
2026
Q1
$465K Sell
9,144
-535
-6% -$25K 0.07% 167
2025
Q4
$285K Sell
9,679
-3,265
-25% -$88.7K 0.05% 207
2025
Q3
$334K Sell
12,944
-1,948
-13% -$54.3K 0.05% 190
2025
Q2
$411K Buy
14,892
+377
+3% +$9.9K 0.07% 165
2025
Q1
$412K Buy
14,515
+3,769
+35% +$134K 0.08% 165
2024
Q4
$447K Buy
10,746
+5,902
+122% +$282K 0.09% 155
2024
Q3
$324K Buy
4,844
+661
+16% +$60.7K 0.06% 189
2024
Q2
$497K Buy
4,183
+774
+23% +$97.9K 0.1% 144
2024
Q1
$363K Buy
+3,409
New +$344K 0.08% 172

Other funds holding MRNA

Probity Advisors's MRNA Position: Q3 2026 in Review

Probity Advisors reduced its Moderna (MRNA) stake by 7.3% in Q3 2026, selling an estimated $70K and leaving 8,297 shares worth $1.6M. The position accounts for 0.23% of the portfolio, ranked #76.

Probity Advisors first reported a position in MRNA in Q1 2024 and has held it in 11 quarters since. 1,048 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Probity Advisors held 8,297 shares of Moderna worth $1.6M as of Q3 2026.
  • Probity Advisors sold 650 Moderna shares in Q3 2026, an estimated $70K.
  • Moderna made up 0.23% of Probity Advisors's portfolio in Q3 2026, its #76 holding.
  • Probity Advisors first reported a position in Moderna in Q1 2024 and has held it in 11 quarters since.
  • 1,048 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Probity Advisors's 13F filing for Q3 2026, filed 23 Oct 2026.